FDA Commissioner Marty Makary has resigned, with Kyle Diamantas, the agency’s top food official, stepping in as acting commissioner. The change ends Makary’s tenure that began in late 2024 and became marked by turnover in senior roles, shifting guidance expectations and debate over the agency’s approach to speeding reviews. The reporting around the departure emphasized uncertainty inside the regulator: analysts cited concerns about predictability for drugmakers, alongside delayed reviews and abrupt guidance reversals. Under Makary, the FDA also backed initiatives tied to AI use in reviews and efforts intended to compress timelines for certain development programs. For biopharma stakeholders, the immediate operational question is how quickly leadership transitions translate into regulatory continuity on ongoing decisions and trial-review expectations. Because FDA policy shifts can reverberate across clinical timelines, the leadership handoff adds another moving piece to an already active regulatory environment. The leadership change also signals continued internal pressure around organizational stability at the FDA, even as the agency maintains ongoing workstreams in drug and biologics review, safety oversight and trial authorization pathways.